Product Description
Aldosterone is a mineralocorticoid hormone produced in the zona glomerulosa of the adrenal cortex that influences water and salt regulation in the body. Aldosterone's primary function is to act on the late distal tubule and collecting duct of nephrons in the kidney, favoring sodium and water reabsorption and potassium excretion while also contributing to acid-base balance. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK470339/)
Mechanisms of Action: MCRA Agonist,Mineralocorticoid Receptor Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous,Oral,Percutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: China | France | Ireland | Italy
Approved Indications: None
Known Adverse Events: None
Company: Alere San Diego
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hypertension|Ischemic Attack, Transient|Ischemic Stroke|Heart Block|Stroke|Coronary Disease|Neuromyelitis Optica|Myocardial Infarction|Heart Failure, Systolic|Heart Failure, Chronic|Type 2 Diabetes|Coronary Stenosis|Heart Failure|Cardiomyopathy, Dilated
Phase 3: Myocardial Infarction|Hypertension|Heart Failure
Phase 1: Inflammation|Heart Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2300074711 | N/A |
Recruiting |
Heart Failure, Chronic |
2026-09-01 |
|
| ChiCTR2200059892 | N/A |
Recruiting |
Kidney Diseases |
2026-04-30 |
|
| WAVE | N/A |
Recruiting |
Hyperaldosteronism |
2025-12-01 |
|
| H.A.P.P.I. Trial | N/A |
Active, not recruiting |
Hyperaldosteronism|Hypertension|Pregnancy Outcomes |
2025-03-01 |